Pulmonary Arterial Hypertension

Journal of the American College of Cardiology

Volumn 51, Issue 16, 2008, Pages 1527-1538

  Chin, Kelly M ^a   Rubin, Lewis J ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BERAPROST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; LETAIRIS; NIFEDIPINE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; SILDENAFIL; SITAXSENTAN; UNCLASSIFIED DRUG; UNIPROST; WARFARIN;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOPPLER ECHOCARDIOGRAPHY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG HALF LIFE; EMBOLISM; FLUSHING; HUMAN; HYPOTENSION; LOW DRUG DOSE; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; NAUSEA; PATHOGENICITY; PORTAL HYPERTENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RENDU OSLER WEBER DISEASE; REVIEW; RISK FACTOR; SIDE EFFECT; THORAX RADIOGRAPHY; THROMBOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VASODILATATION; VOMITING;

ALGORITHMS; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; PULMONARY ARTERY; RISK FACTORS;

EID: 41949104810     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.01.024     Document Type: Review

References (98)

1. Simonneau G., Galie N., Rubin L.J., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 Suppl 1 (2004) 5S-12S
2. Newman J.H., Trembath R.C., Morse J.A., et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 43 Suppl 1 (2004) 33S-39S
3. Austin E.D., and Loyd J.E. Genetics and mediators in pulmonary arterial hypertension. Clin Chest Med 28 (2007) 43-57
4. Grunig E., Janssen B., Mereles D., et al. Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation 102 (2000) 1145-1150
5. Tada Y., Majka S., Carr M., et al. Molecular effects of loss of BMPR2 signaling in smooth muscle in a transgenic mouse model of PAH. Am J Physiol Lung Cell Mol Physiol 292 (2007) L1556-L1563
6. Morty R.E., Nejman B., Kwapiszewska G., et al. Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 27 (2007) 1072-1078
7. Du L., Sullivan C.C., Chu D., et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 348 (2003) 500-509
8. Abdalla S.A., Gallione C.J., Barst R.J., et al. Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia. Eur Respir J 23 (2004) 373-377
9. Abenhaim L., Moride Y., Brenot F., et al., International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 335 (1996) 609-616
10. Rich S., Rubin L., Walker A.M., Schneeweiss S., and Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 117 (2000) 870-874
11. Rothman R.B., Ayestas M.A., Dersch C.M., and Baumann M.H. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation 100 (1999) 869-875
12. Marcos E., Fadel E., and Sanchez O. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 94 (2004) 1263-1270
13. Kawut S.M., Horn E.M., Berekashvili K.K., et al. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther 19 (2006) 370-374
14. Eddahibi S., Guignabert C., Barlier-Mur A.M., et al. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 113 (2006) 1857-1864
15. Chambers C.D., Hernandez-Diaz S., Van Marter L.J., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354 (2006) 579-587
16. Chin K.M., Channick R.N., and Rubin L.J. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?. Chest 130 (2006) 1657-1663
17. Hopkins W.E., Ochoa L.L., Richardson G.W., and Trulock E.P. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 15 (1996) 100-105
18. Oya H., Nagaya N., Uematsu M., et al. Poor prognosis and related factors in adults with Eisenmenger syndrome. Am Heart J 143 (2002) 739-744
19. McLaughlin V.V., Presberg K.W., Doyle R.L., et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 Suppl 1 (2004) 78S-92S
20. Chang B., Schachna L., White B., Wigley F.M., and Wise R.A. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 33 (2006) 269-274
21. Magliano M., Isenberg D.A., and Hillson J. Pulmonary hypertension in autoimmune rheumatic diseases: where are we now?. Arthritis Rheum 46 (2002) 1997-2009
22. Colle I.O., Moreau R., Godinho E., et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 37 (2003) 401-409
23. Halank M., Ewert R., Seyfarth H.J., and Hoeffken G. Portopulmonary hypertension. J Gastroenterol 41 (2006) 837-847
24. Ashfaq M., Chinnakotla S., Rogers L., et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant 7 (2007) 1258-1264
25. Speich R., Jenni R., Opravil M., Pfab M., and Russi E.W. Primary pulmonary hypertension in HIV infection. Chest 100 (1991) 1268-1271
26. Mehta N.J., Khan I.A., Mehta R.N., and Sepkowitz D.A. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 118 (2000) 1133-1141
27. Zuber J.P., Calmy A., Evison J.M., et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 38 (2004) 1178-1185
28. Fawzy M.E., Hassan W., Stefadouros M., Moursi M., El Shaer F., and Chaudhary M.A. Prevalence and fate of severe pulmonary hypertension in 559 consecutive patients with severe rheumatic mitral stenosis undergoing mitral balloon valvotomy. J Heart Valve Dis 13 (2004) 942-947
29. Ghio S., Gavazzi A., Campana C., et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 37 (2001) 183-188
30. Califf R.M., Adams K.F., McKenna W.J., et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 134 (1997) 44-54
31. Kaluski E., Cotter G., Leitman M., et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension-a multi-center randomized study. Cardiology 109 (2008) 273-280
32. Lewis G.D., Shah R., Shahzad K., et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 116 (2007) 1555-1562
33. Neuman Y., Kotliroff A., Bental T., Siegel R.J., David D., and Lishner M. Pulmonary artery pressure and diastolic dysfunction in normal left ventricular systolic function. Int J Cardiol (2007) Jul 20;[E-pub ahead of print].
34. Paulus W.J., Tschope C., Sanderson J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28 (2007) 2539-2550
35. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 (2005) e1-e82
36. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 93 (1980) 391-398
37. Patel N.M., Lederer D.J., Borczuk A.C., and Kawut S.M. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 132 (2007) 998-1006
38. Auger W.R., Kim N.H., Kerr K.M., Test V.J., and Fedullo P.F. Chronic thromboembolic pulmonary hypertension. Clin Chest Med 28 (2007) 255-269
39. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107 (1987) 216-223
40. Thenappan T., Shah S.J., Rich S., and Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 30 (2007) 1103-1110
41. Humbert M., Sitbon O., Chaouat A., et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173 (2006) 1023-1030
42. Berger M., Haimowitz A., Van Tosh A., Berdoff R.L., and Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 6 (1985) 359-365
43. Currie P.J., Seward J.B., Chan K.L., et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 6 (1985) 750-756
44. Hinderliter A.L., Willis IV P.W., Long W., et al. Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. PPH Study Group. Primary pulmonary hypertension. Am J Cardiol 84 (1999) 481-484
45. Sun X.G., Hansen J.E., Oudiz R.J., and Wasserman K. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol 41 (2003) 1028-1035
46. Tunariu N., Gibbs S.J., Win Z., et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 48 (2007) 680-684
47. Worsley D.F., Palevsky H.I., and Alavi A. Ventilation-perfusion lung scanning in the evaluation of pulmonary hypertension. J Nucl Med 35 (1994) 793-796
48. McGoon M., Gutterman D., Steen V., et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 Suppl 1 (2004) 14S-34S
49. Badesch D.B., Abman S.H., Simonneau G., Rubin L.J., and McLaughlin V.V. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131 (2007) 1917-1928
50. Sitbon O., Humbert M., Jais X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111 (2005) 3105-3111
51. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 (1993) 1732-1739
52. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
53. Channick R., Badesch D.B., Tapson V.F., et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J Heart Lung Transplant 20 (2001) 262-263
54. Barst R.J., Langleben D., Badesch D., et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47 (2006) 2049-2056
55. Olschewski H., Galie N., Kramer M., and Rubin L.J. Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: results of the ARIES-2 study. (abstr). Proc Am Thorac Soc 3 (2006) A728
56. McLaughlin V.V., Sitbon O., Badesch D.B., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 (2005) 244-249
57. Sitbon O., McLaughlin V.V., Badesch D.B., et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 60 (2005) 1025-1030
58. Benza R., Frost A., Girgis R., et al. Chronic treatment of pulmonary arterial hypertension with sitaxsentan and bosentan. (abstr). Proc Am Thorac Soc 3 (2006) A729
59. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
60. Christman B.W., McPherson C.D., Newman J.H., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327 (1992) 70-75
61. Barst R.J., Rubin L.J., Long W.A., et al., The Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334 (1996) 296-302
62. McLaughlin V.V., Shillington A., and Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106 (2002) 1477-1482
63. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
64. Barst R.J., McGoon M., McLaughlin V., et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 2119-2125
65. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132 (2000) 425-434
66. Galie N., Beghetti M., Gatzoulis M.A., et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114 (2006) 48-54
67. Singh T.P., Rohit M., Grover A., Malhotra S., and Vijayvergiya R. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 151 (2006) 851-855
68. Apostolopoulou S.C., Manginas A., Cokkinos D.V., and Rammos S. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Heart 93 (2007) 350-354
69. Hoeper M.M., Seyfarth H.J., Hoeffken G., et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 30 (2007) 1096-1102
70. Ashfaq M., Chinnakotla S., Rogers L., et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant 7 (2007) 1258-1264
71. Sitbon O., Gressin V., Speich R., et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 170 (2004) 1212-1217
72. Barbaro G., Lucchini A., Pellicelli A.M., Grisorio B., Giancaspro G., and Barbarini G. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart 92 (2006) 1164-1166
73. Nunes H., Humbert M., Sitbon O., et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 167 (2003) 1433-1439
74. McLaughlin V.V., Oudiz R.J., Frost A., et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174 (2006) 1257-1263
75. Hoeper M.M., Leuchte H., Halank M., et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 28 (2006) 691-694
76. Humbert M., Barst R.J., Robbins I.M., et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24 (2004) 353-359
77. Simonneau G., Burgess G., Collings L., et al. Safety and efficacy of combination therapy with sildenafil and epoprostenol in patients with pulmonary arterial hypertension (PAH). (abstr). Proc Am Thorac Soc 3 (2006) A58
78. Hoeper M.M., Markevych I., Spiekerkoetter E., Welte T., and Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26 (2005) 858-863
79. Johnson S.R., Mehta S., and Granton J.T. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J 28 (2006) 999-1004
80. Badesch D.B., Abman S.H., Ahearn G.S., et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 Suppl 1 (2004) 35S-62S
81. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
82. Raymond R.J., Hinderliter A.L., Willis P.W., et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 39 (2002) 1214-1219
83. Nagaya N., Nishikimi T., and Uematsu M. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102 (2000) 865-870
84. Forfia P.R., Fisher M.R., Mathai S.C., et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 174 (2006) 1034-1041
85. Trulock E.P., Christie J.D., Edwards L.B., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant 26 (2007) 782-795
86. Belenkie I., Dani R., Smith E.R., and Tyberg J.V. Effects of volume loading during experimental acute pulmonary embolism. Circulation 80 (1989) 178-188
87. Molloy D.W., Lee K.Y., Jones D., Penner B., and Prewitt R.M. Effects of noradrenaline and isoproterenol on cardiopulmonary function in a canine model of acute pulmonary hypertension. Chest 88 (1985) 432-435
88. Kurzyna M., Dabrowski M., Bielecki D., et al. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Chest 131 (2007) 977-983
89. Acosta F., Sansano T., Palenciano C.G., et al. Effects of dobutamine on right ventricular function and pulmonary circulation in pulmonary hypertension during liver transplantation. Transplant Proc 37 (2005) 3869-3870
90. Hirsch L.J., Rooney M.W., Wat S.S., Kleinmann B., and Mathru M. Norepinephrine and phenylephrine effects on right ventricular function in experimental canine pulmonary embolism. Chest 100 (1991) 796-801
91. Leather H.A., Segers P., Berends N., Vandermeersch E., and Wouters P.F. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med 30 (2002) 2548-2552
92. Rich S., Gubin S., and Hart K. The effects of phenylephrine on right ventricular performance in patients with pulmonary hypertension. Chest 98 (1990) 1102-1106
93. Petkov V., Mosgoeller W., Ziesche R., et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111 (2003) 1339-1346
94. Schermuly R.T., Dony E., Ghofrani H.A., et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115 (2005) 2811-2821
95. Guignabert C., Izikki M., Tu L.I., et al. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 98 (2006) 1323-1330
96. Abe K., Shimokawa H., Morikawa K., et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 94 (2004) 385-393
97. Wang X.X., Zhang F.R., Shang Y.P., et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol 49 (2007) 1566-1571
98. Zhao Y.D., Courtman D.W., Deng Y., Kugathasan L., Zhang Q., and Stewart D.J. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 96 (2005) 442-450